Ainos, Inc. — Filing Summary
Entity and period: The supplied filing text is for Amarillo Biosciences, Inc. (ABI), not Ainos, Inc. It is an annual Form 10-K for the fiscal year ended December 31, 2018, filed April 16, 2019; it does not report a standalone 2018 fourth quarter.
Business context
ABI develops healthcare products through Pharmaceutical, Medical, and Consumer divisions. Its historic focus is low-dose oral interferon, while its newer activities include diabetes-related treatment development, wound-care product distribution in Taiwan, and liposomal nutraceutical sales. In 2018, ABI consolidated ACTS Global and established its Taiwan branch.
Financial results and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $77,724 | $250,928 |
| Gross profit | $12,847 | $190,612 |
| Gross margin | 16.5% | 76.0% |
| Operating expenses | $1,347,523 | $770,375 |
| Operating loss | $(1,334,676) | $(579,763) |
| Net loss | $(1,338,639) | $(617,375) |
| Net loss per share | $(0.04) | $(0.03) |
| Cash used in operations | $(1,009,198) | $(484,568) |
Cash and cash equivalents were $1,276,654 at year-end, down from $2,038,150. Working capital was $569,613, versus $261,412 in 2017. Total current liabilities were $733,621, including $513,356 of unsecured, on-demand convertible notes owed to CEO Stephen Chen and $104,952 in investor advances. The company reported an approximate monthly burn rate of $65,000–$75,000 and estimated short-term project financing needs of $3 million–$5 million. No interest-bearing bank debt is identified in the supplied text.
Revenue fell 69% year over year, and gross profit fell 93%. 2018 revenue was primarily from liposomal nutraceuticals, with 50% from one customer; 2017 revenue came from metabolic treatment equipment sold to one customer. SG&A increased 70.7% to $1,314,932, and R&D was $32,591, versus none in 2017. The 2018 cash-flow statement reports financing cash inflow of $254,979, mainly from equity proceeds and investor advances, partly offset by note repayments.
Outlook, risks, and unusual items
- The independent auditor and management cited substantial doubt about ABI’s ability to continue as a going concern, given recurring losses, limited revenue, and the need for additional financing. The statements include no adjustments for the outcome of that uncertainty.
- Further interferon trials and commercialization are on hold until ABI finds a new cGMP interferon supplier. A replacement source would require comparability work and additional clinical trials; cost and timing are uncertain.
- Management described plans to pursue Asian-market growth, including pulsatile insulin treatment and TissueAid wound-closure distribution in Taiwan. These are plans, not guaranteed results; the filing gives no quantified revenue or earnings guidance.
- ABI has significant regulatory, product-development, funding, customer-concentration, and competition risks. It also disclosed $3,458,214 potentially dilutive shares excluded from diluted loss per share as antidilutive.
- In 2018 the company issued 5.44 million shares for cash or previously received subscriptions, converted $178,125 of related-party debt into shares, and issued 539,447 shares in the ACTS transaction. It adopted option plans and granted 4,945,000 options; unrecognized option expense was $1,775,222. These instruments and future equity financing may dilute shareholders.
- Management concluded disclosure controls and internal control over financial reporting were ineffective, citing insufficient technical accounting expertise and inadequate segregation of duties. The auditor did not attest to internal control effectiveness.
- ABI wrote off approximately $15,967 of net patent carrying value for dropped patents. The company reported no litigation and no material environmental-compliance costs.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Amarillo Biosciences, Inc., despite the Ainos, Inc. request metadata.
- Review the auditor’s going-concern qualification, financing requirements, and the company’s subsequent ability to raise capital.
- Assess whether ABI secured a replacement interferon supplier and whether planned clinical work or commercialization resumed.
- Check customer concentration, revenue sustainability, and progress of the Taiwan medical and consumer-product businesses.
- Reconcile reported share counts and assess dilution from outstanding notes, warrants, options, and future financing.
- Review related-party lending, compensation, ACTS consideration, and the disclosed internal-control material weaknesses.